Autoantigens and immune pathways in rheumatoid arthritis
- PMID: 12678429
Autoantigens and immune pathways in rheumatoid arthritis
Abstract
Rheumatoid arthritis (RA) is a major systemic autoimmune disease. A plethora of putative autoantigens has been described by the reactivity of antibodies present in the sera of patients. Despite this there is little evidence implicating most of them in its pathogenesis. Autoantigens fall into two major groups: first, those that are associated with the joint, such as collagen type II, human chondrocyte glycoprotein 39, and proteoglycans, for which a pathogenic role is easily understood; and second, those proteins not associated with the joint. Of these there are three groups: (1) highly conserved foreign antigens with human homologues, such as heat shock proteins (HSPs), in which the initiating antigenic stimulus may be through infection; (2) post-translationally altered proteins, such as citrullinated filaggrin, to which autoantibodies show high specificity but low sensitivity for RA and immunoglobulin G; and (3) ubiquitous proteins, such as glucose-6-phosphate isomerase, p205, and HSPs secreted during stress, such as BiP. The mechanisms by which such ubiquitous antigens cause pathology predominantly in the joints are difficult to understand. Autoantibodies, such as rheumatoid factors, that form immune complexes resulting in activation of phagocytic cells or the complement system, may cause joint pathology by deposition in the joints. Such an explanation, however, is not available for all of these autoantigens. It is possible that pathology may be the outcome of disturbed immunoregulation.
Similar articles
-
Rheumatoid arthritis and systemic lupus erythematosus as immune complex diseases.Bull NYU Hosp Jt Dis. 2009;67(3):251-3. Bull NYU Hosp Jt Dis. 2009. PMID: 19852746 Review.
-
Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach.Arthritis Res Ther. 2006;8(6):R175. doi: 10.1186/ar2085. Arthritis Res Ther. 2006. PMID: 17125526 Free PMC article.
-
Optimization of high-throughput autoantibody profiling for the discovery of novel antigenic targets in rheumatoid arthritis.Ann N Y Acad Sci. 2009 Sep;1173:92-102. doi: 10.1111/j.1749-6632.2009.04654.x. Ann N Y Acad Sci. 2009. PMID: 19758137
-
Autoimmune reactions and rheumatoid arthritis.Eur J Rheumatol Inflamm. 1982;5(4):439-56. Eur J Rheumatol Inflamm. 1982. PMID: 6983963
-
Autoantibodies in rheumatoid arthritis: a review.Biomed Pharmacother. 2006 Dec;60(10):648-55. doi: 10.1016/j.biopha.2006.09.002. Epub 2006 Oct 10. Biomed Pharmacother. 2006. PMID: 17064873 Review.
Cited by
-
Regulation of autoantibody activity by the IL-23-TH17 axis determines the onset of autoimmune disease.Nat Immunol. 2017 Jan;18(1):104-113. doi: 10.1038/ni.3579. Epub 2016 Nov 7. Nat Immunol. 2017. PMID: 27820809 Free PMC article.
-
Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis.Mol Ther. 2009 Apr;17(4):632-40. doi: 10.1038/mt.2009.299. Epub 2009 Jan 27. Mol Ther. 2009. PMID: 19174762 Free PMC article.
-
Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis : studies in mice with K/BxN serum-induced arthritis.Arthritis Rheum. 2013 Jul;65(7):1736-46. doi: 10.1002/art.37981. Arthritis Rheum. 2013. PMID: 23633118 Free PMC article.
-
Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach.J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12. doi: 10.1007/s10928-013-9341-1. J Pharmacokinet Pharmacodyn. 2013. PMID: 24233383 Free PMC article.
-
Cellular response to prosthetic wear debris differs in patients with and without rheumatoid arthritis.Arthritis Rheum. 2012 Apr;64(4):1005-14. doi: 10.1002/art.33459. Epub 2011 Nov 29. Arthritis Rheum. 2012. PMID: 22127818 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical